INCY News and Press, Incyte Corporation From 08/04/20

Image source: The Motley Fool. Incyte Corp   (NASDAQ: INCY) Q2 2020 Earnings Call Aug 4, 2020 , 8:00 a.m. ET Operator Continue reading

Incyte Corporation (INCY) Q2 2020 Earnings Conference Call August 04, 2020 08:00 AM ET Company Participants Mike Booth - Head of Investor Relations Hervé Hoppenot - Chairman, President & Chief Executive Officer Barry Flannelly - Executive Vice President, General Manager,...

The following slide deck was published by Incyte Corporation in conjunction with their 2020 Q2 earnings Read more ...

Incyte ( INCY ) Q2 results : More news on: Incyte Corporation, Healthcare stocks news, Earnings news and commentary, , Read more ...

Incyte (NASDAQ: INCY ) : Q2 Non-GAAP EPS of $1.24 beats by $0.37 ; GAAP EPS of $1.32 beats by $0.65 . More news on: Incyte Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...

Total product and royalty revenues of $593 million (+16% vs Q2 2019) for the quarter ended June 30, 2020; Jakafi ® (ruxolitinib) revenues of $474 million in Q2 2020 (+16% vs Q2 2019) Monjuvi ® (tafasitamab-cxix; collaboration with MorphoSys) approved by U.S. FDA; launc...

Incyte (NASDAQ: INCY ) is scheduled to announce Q2 earnings results on Tuesday, August 4th, before market open. The consensus EPS Estimate is $0.87 (+16.0% Y/Y) and the consensus Revenue Estimate is $614.07M (+15.9% Y/Y). Over the last 2 years, INCY has beaten EPS estimates 75% of th...

The FDA approval of MorphoSys' Monjuvi, in a treatment in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL), has triggered a $25 million milestone payment and royalty on net sales for Xencor (NASDAQ: XNCR ) , the co. announce...

Morphosys AG (NASDAQ: MOR ) and collaboration partner/licensee Incyte (NASDAQ: INCY ) announce the FDA nod for Monjuvi (tafasitamab-cxix), combined with lenalidomide, for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specif...

- First FDA approval of a second-line treatment for adult patients with relapsed or refractory DLBCL, helping fill a high unmet medical need - FDA granted Monjuvi Fast Track, Breakthrough Therapy and Priority Review designations - MorphoSys and Incyte will co-commercialize Monju...